TrialBMC pulmonary medicine2021

Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.

Ulrike Schmid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.